Abstract
Peripheral sympathetic nervous system tumors are the most common extracranial solid tumors of childhood and include neuroblastoma, ganglioneuroblastoma, and ganglioneuroma. Surgery is the only effective therapy for ganglioneuroma, which may be challenging due to the location of the tumor and involvement of surrounding structures. Thus, there is a need for well-tolerated presurgical therapies that could reduce the size and extent of ganglioneuroma and therefore limit surgical morbidity. Here, we found that an AKT–mTOR–S6 pathway was active in human ganglioneuroma but not neuroblastoma samples. Zebrafish transgenic for constitutively activated myr-Akt2 in the sympathetic nervous system were found to develop ganglioneuroma without progression to neuroblastoma. Inhibition of the downstream AKT target, mTOR, in zebrafish with ganglioneuroma effectively reduced the tumor burden. Our results implicate activated AKT as a tumorigenic driver in ganglioneuroma. We propose a clinical trial of mTOR inhibitors as a means to shrink large ganglioneuromas before resection in order to reduce surgical morbidity.
Funding Information
  • National Institutes of Health (5 P30 CA06516)
  • National Institutes of Health (R01-CA180692)
  • Pediatric Cancer Research Foundation
  • Rally Foundation for Childhood Cancer Research
  • Open Hands Overflowing Hearts
  • Rally Foundation for Childhood Cancer Research
  • CureSearch for Children’s Cancer
  • American Society of Clinical Oncology
  • Damon Runyon-Sohn (DRSG-24-18)
  • Alex’s Lemonade Stand Foundation for Childhood Cancer

This publication has 63 references indexed in Scilit: